195 related articles for article (PubMed ID: 37380911)
1. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
Boughey JC; Yu H; Dugan CL; Piltin MA; Postlewait L; Son JD; Edmiston KK; Godellas CV; Lee MC; Carr MJ; Tonneson JE; Crown A; Lancaster RB; Woriax HE; Ewing CA; Chau HS; Patterson AK; Wong JM; Alvarado MD; Yang RL; Chan TW; Sheade JB; Ahrendt GM; Larson KE; Switalla K; Tuttle TM; Tchou JC; Rao R; Tamirisa N; Singh P; Gould RE; Terando A; Sauder C; Hewitt K; Chiba A; Esserman LJ; Mukhtar RA
Ann Surg Oncol; 2023 Oct; 30(11):6401-6410. PubMed ID: 37380911
[TBL] [Abstract][Full Text] [Related]
2. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
[TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
4. Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer.
Piltin MA; Hoskin TL; Day CN; Davis J; Boughey JC
Ann Surg Oncol; 2020 Nov; 27(12):4795-4801. PubMed ID: 32779055
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative assessment of sentinel lymph node by one-step nucleic acid amplification in breast cancer patients after neoadjuvant treatment reduces the need for a second surgery for axillary lymph node dissection.
Espinosa-Bravo M; Navarro-Cecilia J; Ramos Boyero M; Diaz-Botero S; Dueñas Rodríguez B; Luque López C; Ramos Grande T; Ruano Perez R; Peg V; Rubio IT
Breast; 2017 Feb; 31():40-45. PubMed ID: 27810698
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
8. Conservative axillary surgery is emerging in the surgical management of breast cancer.
Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E; Haba Y
Breast Cancer; 2023 Jan; 30(1):14-22. PubMed ID: 36342647
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
[TBL] [Abstract][Full Text] [Related]
10. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
11. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
Moo TA; Edelweiss M; Hajiyeva S; Stempel M; Raiss M; Zabor EC; Barrio A; Morrow M
Ann Surg Oncol; 2018 Jun; 25(6):1488-1494. PubMed ID: 29572705
[TBL] [Abstract][Full Text] [Related]
12. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Boughey JC
Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Damin AP; Zancan M; Melo MP; Biazus JV
Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
[TBL] [Abstract][Full Text] [Related]
14. Practice Patterns of Radiation Field Design for Sentinel Lymph Node-Positive Early-Stage Breast Cancer.
Azghadi S; Daly M; Mayadev J
Clin Breast Cancer; 2016 Oct; 16(5):410-417.e3. PubMed ID: 27266803
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
16. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
Breast J; 2022; 2022():1507881. PubMed ID: 36051467
[TBL] [Abstract][Full Text] [Related]
17. Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer.
Sanders SB; Hoskin TL; Stafford AP; Boughey JC
Ann Surg Oncol; 2022 Nov; 29(12):7769-7778. PubMed ID: 35834142
[TBL] [Abstract][Full Text] [Related]
18. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
[TBL] [Abstract][Full Text] [Related]
19. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.
Sargent RE; Siegel E; Ito F; Kramme K; Kraft E; Hendrix V; Carr AA; Nelson ME; Bian SX; Jayachandran P; Sener SF
J Surg Oncol; 2023 Jul; 128(1):9-15. PubMed ID: 36933187
[TBL] [Abstract][Full Text] [Related]
20. Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy.
Cao XS; Li HJ; Cong BB; Sun X; Qiu PF; Liu YB; Wang CJ; Wang YS
Oncotarget; 2016 Nov; 7(45):74074-74081. PubMed ID: 27738336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]